Business Description
Celldex Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US15117B2025
Total Employee Number:
198Description
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 236.61 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 26.78 | |||||
Beneish M-Score | -4.86 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -22.8 | |||||
3-Year EBITDA Growth Rate | -24.4 | |||||
3-Year EPS without NRI Growth Rate | -23.7 | |||||
3-Year FCF Growth Rate | -12.6 | |||||
3-Year Book Growth Rate | 4.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 373.03 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 86.2 | |||||
9-Day RSI | 83.3 | |||||
14-Day RSI | 77.77 | |||||
3-1 Month Momentum % | -1.21 | |||||
6-1 Month Momentum % | 7.46 | |||||
12-1 Month Momentum % | 31.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.92 | |||||
Quick Ratio | 8.92 | |||||
Cash Ratio | 8.77 | |||||
Days Sales Outstanding | 294.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.1 | |||||
Shareholder Yield % | 0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -35688.45 | |||||
Net Margin % | -32753.58 | |||||
EBITDA Margin % | -35299.65 | |||||
FCF Margin % | -25959.95 | |||||
OCF Margin % | -25490.25 | |||||
ROE % | -48.24 | |||||
ROA % | -44.67 | |||||
ROIC % | -623.75 | |||||
3-Year ROIIC % | -1323.19 | |||||
ROC (Joel Greenblatt) % | -3829.48 | |||||
ROCE % | -52.2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2951.54 | |||||
PB Ratio | 5.6 | |||||
Price-to-Tangible-Book | 5.95 | |||||
EV-to-EBIT | -8.29 | |||||
EV-to-Forward-EBIT | -6.87 | |||||
EV-to-EBITDA | -8.38 | |||||
EV-to-Forward-EBITDA | -6.87 | |||||
EV-to-Revenue | 2958.65 | |||||
EV-to-Forward-Revenue | 589.01 | |||||
EV-to-FCF | -11.32 | |||||
Price-to-GF-Value | 5.38 | |||||
Price-to-Median-PS-Value | 24.45 | |||||
| Price-to-Net-Current-Asset-Value | 6.32 | |||||
| Price-to-Net-Cash | 6.43 | |||||
Earnings Yield (Greenblatt) % | -12.06 | |||||
FCF Yield % | -7.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celldex Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.749 | ||
| EPS (TTM) (€) | -3.661 | ||
| Beta | 0.8472 | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.26 | ||
| Volatility % | 38.39 | ||
| 14-Day RSI | 77.77 | ||
| 14-Day ATR (€) | 0.604116 | ||
| 20-Day SMA (€) | 28.3565 | ||
| 12-1 Month Momentum % | 31.72 | ||
| 52-Week Range (€) | 17 - 33.01 | ||
| Shares Outstanding (Mil) | 78.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celldex Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celldex Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 33 days | ||
| General meeting for 2026 | 2026-06-25 09:00 | 29.19 (+2.17%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 28.43 (+0.00%) | ||
| H.C. Wainwright\'s 4th Annual Inflammatory Skin Disease Virtual Conference | 2026-04-14 15:30 | 27.17 (+0.00%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 15:40 | 25.20 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 09:10 | 25.40 (+0.00%) | ||
| Annual report for 2025 | 2026-02-25 | 20.40 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 20.40 (+0.00%) | ||
| Guidance call for 2026 | 2026-02-11 15:30 | 20.60 (+0.00%) |
Show
Entries
Celldex Therapeutics Inc Frequently Asked Questions
What is Celldex Therapeutics Inc(FRA:TCE2)'s stock price today?
The current price of FRA:TCE2 is €33.01. The 52 week high of FRA:TCE2 is €33.01 and 52 week low is €17.00.
When is next earnings date of Celldex Therapeutics Inc(FRA:TCE2)?
The next earnings date of Celldex Therapeutics Inc(FRA:TCE2) is 2026-08-07 Est..
Does Celldex Therapeutics Inc(FRA:TCE2) pay dividends? If so, how much?
Celldex Therapeutics Inc(FRA:TCE2) does not pay dividend.
Press Release
Articles on Celldex Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers